Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: a systematic review and Meta-analysis.
10.19540/j.cnki.cjcmm.20180925.008
- Author:
Po HUANG
1
;
Bo LI
2
;
Yu-Hong GUO
3
;
Shuo FENG
4
;
Jing HU
4
;
Qing-Quan LIU
5
Author Information
1. Capital Medical University Beijing 100069, China Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University Beijing 100010, China.
2. Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University Beijing 100010, China Beijing Institute of Traditional Chinese Medicine Beijing 100010, China.
3. Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University Beijing 100010, China.
4. Beijing Institute of Traditional Chinese Medicine Beijing 100010, China.
5. Capital Medical University Beijing 100069, China Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University Beijing 100010, China Beijing Institute of Traditional Chinese Medicine Beijing 100010, China Beijing Key Laboratory of Infectious Diseases Treated by Traditional Chinese Medicine Beijing 100010, China.
- Publication Type:Journal Article
- Keywords:
benign memory disorders;
efficacy;
huperzine A;
mild cognitive impairment;
safety;
systematic review
- MeSH:
Alkaloids;
therapeutic use;
Cognitive Dysfunction;
drug therapy;
Humans;
Memory;
Randomized Controlled Trials as Topic;
Sesquiterpenes;
therapeutic use
- From:
China Journal of Chinese Materia Medica
2019;44(3):582-588
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the efficacy and safety of huperzine in treating patients with mild cognitive impairment. The randomized controlled trials(RCT) were retrieved from EMbase, Cochrane Library, PubMed, CNKI, Wanfang and VIP. The methodology quality of the included studies was evaluated, and a Meta-analysis was performed using RevMan 5.3 software. A total of nine RCTs were included. The Meta-analysis results showed that compared with placebo, Huperzine significantly increased the scores of memory quotient(MQ) and mini-mental state examination(MMSE). However, there was no statistical difference between oral tablet and capsule. Compared with placebo, huperzine A was superior in the scores of MQ and MMSE. Huperzine is safe with mild side effects. Due to the low quality of original studies, more high-quality studies are needed to verify its efficacy.
